ROCHE HLDGS AG (RHHBY)

32.61
0.19 0.59
OTC
Prev Close 32.42
Open 32.38
Day Low/High 32.28 / 32.63
52 Wk Low/High 26.30 / 32.72
Volume 762.00K
Exchange OTC
Shares Outstanding 702.56B
Market Cap 182.22B
Div & Yield N.A. (N.A)
Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plus Bendamustine And Rituxan (BR) Increased Complete Response Rates Compared To BR Alone In Previously Treated Aggressive Lymphoma

Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plus Bendamustine And Rituxan (BR) Increased Complete Response Rates Compared To BR Alone In Previously Treated Aggressive Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the randomized Phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus...

Genentech's HEMLIBRA (emicizumab-kxwh) Continued To Substantially Reduce Bleeds In People With Hemophilia A With Inhibitors

Genentech's HEMLIBRA (emicizumab-kxwh) Continued To Substantially Reduce Bleeds In People With Hemophilia A With Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from the ongoing HEMLIBRA ® (emicizumab-kxwh) clinical development program were presented at the 59th American Society...

Phase III IMpower150 Study Showed TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Chemotherapy Reduced The Risk Of Disease Worsening Or Death By 38 Percent For People With A Type Of Advanced Lung Cancer

Phase III IMpower150 Study Showed TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Chemotherapy Reduced The Risk Of Disease Worsening Or Death By 38 Percent For People With A Type Of Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the positive, pivotal Phase III IMpower150 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) plus...

Genentech's HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds In Phase III Study In Hemophilia A

Genentech's HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds In Phase III Study In Hemophilia A

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive interim results from the Phase III HAVEN 4 study evaluating HEMLIBRA ® (emicizumab-kxwh) prophylaxis dosed once every four...

FDA Grants Genentech's Avastin Full Approval For Most Aggressive Form Of Brain Cancer

FDA Grants Genentech's Avastin Full Approval For Most Aggressive Form Of Brain Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche sees success in trials for its cancer and hemophilia drugs

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (atezolizumab) And Avastin (bevacizumab) Plus Chemotherapy Significantly Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Lung Cancer

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (atezolizumab) And Avastin (bevacizumab) Plus Chemotherapy Significantly Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination...

Genentech's HEMLIBRA (emicizumab-kxwh) Significantly Reduced Bleeds In Phase III Study In Hemophilia A

Genentech's HEMLIBRA (emicizumab-kxwh) Significantly Reduced Bleeds In Phase III Study In Hemophilia A

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III HAVEN 3 study evaluating HEMLIBRA ® (emicizumab-kxwh) in adults and adolescents (aged 12 years or...

FDA Approves Genentech's Gazyva For Previously Untreated Advanced Follicular Lymphoma

FDA Approves Genentech's Gazyva For Previously Untreated Advanced Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

(Photo: Business Wire)

(Photo: Business Wire)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Approves Genentech's Alecensa (Alectinib) As First-Line Treatment For People With Specific Type Of Lung Cancer

FDA Approves Genentech's Alecensa (Alectinib) As First-Line Treatment For People With Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Zelboraf (Vemurafenib) For Erdheim-Chester Disease With BRAF V600 Mutation

FDA Approves Zelboraf (Vemurafenib) For Erdheim-Chester Disease With BRAF V600 Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech To Present New Data Across A Range Of Blood Diseases At The American Society Of Hematology (ASH) 2017 Annual Meeting

Genentech To Present New Data Across A Range Of Blood Diseases At The American Society Of Hematology (ASH) 2017 Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on its approved and investigational medicines for blood diseases will be presented at the 59 th American Society of...

New OCREVUS (Ocrelizumab) Data At ECTRIMS Advance Clinical Understanding Of Underlying Progression In Multiple Sclerosis

New OCREVUS (Ocrelizumab) Data At ECTRIMS Advance Clinical Understanding Of Underlying Progression In Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data are being presented at the 7th Joint European Committee for Treatment and Research in Multiple...

FDA Accepts Genentech's Supplemental Biologics License Application For Avastin As A Front-Line Treatment For Women With Advanced Ovarian Cancer

FDA Accepts Genentech's Supplemental Biologics License Application For Avastin As A Front-Line Treatment For Women With Advanced Ovarian Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech To Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data In Relapsing And Primary Progressive Forms Of Multiple Sclerosis At ECTRIMS

Genentech To Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data In Relapsing And Primary Progressive Forms Of Multiple Sclerosis At ECTRIMS

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS® (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be...

Pfizer Consumer Unit Worth as Much as $14 Billion

Pfizer Consumer Unit Worth as Much as $14 Billion

A deal would give the company capital to do more deals but the decision also keeps the company's recently scratched plans to split into two separate companies alive. The division itself had about $3.4 billion in 2016 sales and houses brands such as Advil, Chaptstick, Centrum and Preparation H, among others.

FDA Grants Priority Review For Genentech's Perjeta (Pertuzumab) For Adjuvant Treatment Of HER2-Positive Early Breast Cancer

FDA Grants Priority Review For Genentech's Perjeta (Pertuzumab) For Adjuvant Treatment Of HER2-Positive Early Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.

Apple, Fitbit Part of FDA Pilot Program to Expedite Health Devices to Market

Apple, Fitbit Part of FDA Pilot Program to Expedite Health Devices to Market

Other companies including Samsung Electronics, Alphabet's Verily Life Sciences, Johnson & Johnson and Roche Holding will also participate in the program.

Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic Leukemia Live Longer Without Their Disease Worsening Compared To Bendamustine Plus Rituxan

Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic Leukemia Live Longer Without Their Disease Worsening Compared To Bendamustine Plus Rituxan

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MURANO study, which evaluated Venclexta ™ (venetoclax) in combination with Rituxan ® (rituximab) in people...

Genentech Provides Update On First Lampalizumab Phase III Study For Geographic Atrophy, An Advanced Form Of Age-Related Macular Degeneration

Genentech Provides Update On First Lampalizumab Phase III Study For Geographic Atrophy, An Advanced Form Of Age-Related Macular Degeneration

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and efficacy of...

FDA Approves Genentech's Actemra (Tocilizumab) For The Treatment Of CAR T Cell-Induced Cytokine Release Syndrome

FDA Approves Genentech's Actemra (Tocilizumab) For The Treatment Of CAR T Cell-Induced Cytokine Release Syndrome

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Grants Priority Review For Genentech's Gazyva In Previously Untreated Follicular Lymphoma

FDA Grants Priority Review For Genentech's Gazyva In Previously Untreated Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Grants Priority Review To Genentech's Emicizumab For Hemophilia A With Inhibitors

FDA Grants Priority Review To Genentech's Emicizumab For Hemophilia A With Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

J&J's Janssen Pharmaceuticals will oppose Florida's use of its drug in a Thursday execution.

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

FDA Grants Priority Review And Breakthrough Therapy Designation For Zelboraf (vemurafenib) In Erdheim-Chester Disease With BRAF V600 Mutation

FDA Grants Priority Review And Breakthrough Therapy Designation For Zelboraf (vemurafenib) In Erdheim-Chester Disease With BRAF V600 Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of The August 7, 2017 Deadline In The Class Action Lawsuit Against Roche Holding AG

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of The August 7, 2017 Deadline In The Class Action Lawsuit Against Roche Holding AG

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Roche Holding AG ("Roche" or the "Company") (OTC: RHHBY) securities between March 2, 2017...

FDA Grants Genentech's Alecensa Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer

FDA Grants Genentech's Alecensa Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Roche Lifts Full-Year Outlook After Solid Q2 Earnings Beat

Roche Lifts Full-Year Outlook After Solid Q2 Earnings Beat

Roche sees 'mid-single' digit sales growth in second half.